Is TETRALOGIC PHARMACEUTICALS CORP (OTCMKTS:TLOG) a Buy? The Stock Reported more Sellers

June 12, 2018 - By Stephen Andrade

The stock of TETRALOGIC PHARMACEUTICALS CORP (OTCMKTS:TLOG) registered an increase of 58.13% in short interest. TLOG’s total short interest was 105,000 shares in June as published by FINRA. Its up 58.13% from 66,400 shares, reported previously. With 125,300 shares average volume, it will take short sellers 1 days to cover their TLOG’s short positions. The short interest to TETRALOGIC PHARMACEUTICALS CORP’s float is 0.7%.

It closed at $0.023 lastly. It is down 0.00% since June 12, 2017 and is . It has underperformed by 12.57% the S&P500.

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. The company has market cap of $562,697. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. It currently has negative earnings. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: